secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001804220-21-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37
-------------------------------------------------------------------------

- Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).
- EYLEA U.S. net sales $1.47B (+12% YoY); Dupixent global net sales (Sanofi) $1.66B (+55% YoY).
- REGEN-COV contributed $804M (U.S. product sales $677M + Roche profit share); new U.S. government supply agreement for 1.4M doses.
- Pipeline: FDA expanded Dupixent to children 6-11 with asthma; positive Phase 3 data in CSU, EoE, prurigo nodularis; REGEN-COV BLA accepted for priority review.
- FY 2021 guidance updated: R&D lowered to $2.845-2.915B GAAP; SG&A narrowed to $1.76-1.83B; gross margin ~87.5% GAAP; capex reduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/0001804220-21-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/regn-20211104.htm
  HTML page:      https://secwatch.observer/filing/0001804220-21-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer